Oslo 27.05.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that patient enrollment in the first clinical study of its second HIV vaccine, Vacc-C5, is now completed, with 36 HIV infected patients enrolled at Oslo University Hospital. Thirty six HIV Patients Participate at Oslo University Hospital Vacc-C5 has been developed with the aim to induce …
Oslo 29.04.2013 – Bionor Pharma ASA (OSE: BIONOR) announced today that all patients are now enrolled in the study for reboost of patients from the previously conducted phase II clinical study with Vacc-4x. Thirty-three Patients Participate at 10 Clinics in USA and Europe The 33 patients are recruited at 10 clinics in USA, Germany, England, …
Findings Provide Further Support for the Rationale Behind Bionor Pharma`s Second HIV Vaccine, Vacc-C5 (Oslo, 5 April 2013) Bionor Pharma ASA (OSE: BIONOR) today announced that their scientific work entitled “The C5 region of HIV-1 gp120 shares homology with the shared epitope of HLA-DRß1 and activates immune responses. Anti-C5 antibodies correlate with protection from HIV-1 disease …
